Sarcopenia, Telomere Length and Mortality: Nhanes 1999–2002

Batsis, John A.; MacKenzie, Todd A.; Emeny, Rebecca T.; Rippberger, P.; López-Jiménez, Francisco; Bartels, Stephen J.

doi:10.1093/geroni/igx004.773

Cited by 6 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This makes the determining and recognizing muscle loss more difficult (24). Prevalence of sarcopenic obesity has been found to be 18.1% in females and 42.9% in males (4). In a study trying to put forward the prevalence of sarcopenic obesity in patients with cancer, functional capacity of sarcopenic obese patients has been found to be lower than nonsarcopenic obese ones, and it has also been indicated that this condition is an independent predictor for survival (25).…”

Section: Sexmentioning

confidence: 99%

“…Severe loss of muscles is a condition accelerating tumor progression, influencing survival, and increasing frequency of toxicity due to chemotherapy (CT) in oncologic patients (2). Sarcopenic obesity, which is a subclass of sarcopenia, may cause limitation of functions and mobility in elderly (3) and increases mortality rates due to all reasons in women (4). There are approaches developed in diagnosing and evaluating sarcopenic patients (5).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of sarcopenia, sarcopenic obesity, and phase angle in geriatric gastrointestinal cancer patients: before and after chemotherapy

Bıçaklı¹

2019

Turk J Med Sci

View full text Add to dashboard Cite

Background/aim: The purpose of this study was to determine sarcopenia, sarcopenic obesity and phase angle (PA) and the influence of chemotherapy (CT) on anthropometric measurements and and the PA in in geriatric patients with gastrointestinal (GI) cancer. Material and methods: The anthropometric measurements, calf circumference (CC), upper midarm circumference (UMAC), and hand grip strength (HGS), have been measured to understand muscle function of 153 patients (mean age of 70.5 ± 5.6 years, 28.8% female, 71.2% male). Sarcopenia and PA measurements have been evaluated by bioelectrical impedance analyses. The same evaluations were checked again after 1 cycle of CT (min: 4, max: 6 weeks). Results: Patient population consisted of colorectal (51,6%), gastric (26.8%), pancreas (11.8%), liver (7.2%), and biliary tract cancer (2%).

show abstract

Section: Sexmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Evaluation of sarcopenia, sarcopenic obesity, and phase angle in geriatric gastrointestinal cancer patients: before and after chemotherapy

Bıçaklı¹

2019

Turk J Med Sci

View full text Add to dashboard Cite

show abstract

“…The prevalence of sarcopenic obesity using each definition are presented in Table 2. Prevalence of sarcopenic obesity ranged from 0.1% based on Newman et al (2003) to 85.3% based on Kim et al (2009) in males and 0% based on definitions from Batsis et al and Zoico et al (Newman et al, 2003;Zoico et al, 2004;Batsis et al, 2015) to 80.4% based on Kim et al in females (Kim et al, 2009).…”

Section: Prevalence Of Sarcopenic Obesitymentioning

confidence: 99%

“…Although differences in body composition among ethnicities may exist, definitions were not excluded based on ethnicity to ensure our findings are inclusive and can inform future research regarding performance of each published definition, a similar approach to others (Batsis et al, 2013;Khor et al, 2020). Many previous publications that established sarcopenic obesity cut points were developed from individuals with a wide variety of ethnicities (Baumgartner et al, 1998(Baumgartner et al, , 2004Newman et al, 2003;Levine and Crimmins, 2012;Prado et al, 2014;Batsis et al, 2015;Siervo et al, 2015).…”

Section: Sarcopenic Obesity Definitionsmentioning

confidence: 99%

“…Eleven studies that defined sarcopenic obesity based upon body composition derived from DXA were used in the present analysis (Baumgartner et al, 1998(Baumgartner et al, , 2004Newman et al, 2003;Zoico et al, 2004;Bouchard et al, 2009;Kim et al, 2009;Levine and Crimmins, 2012;Prado et al, 2014;Batsis et al, 2015;Oh et al, 2015;Siervo et al, 2015). As many of these publications developed multiple definitions of sarcopenic obesity, a total of 29 definitions were applied to the CLSA sample.…”

Section: Sarcopenic Obesity Definitionsmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of Sarcopenic Obesity Using Different Definitions and the Relationship With Strength and Physical Performance in the Canadian Longitudinal Study of Aging

et al. 2021

View full text Add to dashboard Cite

Sarcopenic obesity is associated with several negative health outcomes. However, the prevalence of this condition – and the relationship to physical performance parameters – varies across definitions. The aim of this cross-sectional investigation was to describe the prevalence of sarcopenic obesity using different published definitions and their relationship with handgrip strength and walking speed in older Canadian adults. Individuals aged 65+ in the Canadian Longitudinal Study on Aging (n = 11,803; 49.6% male, 50.4% female) were included. Body composition was measured using dual X-ray absorptiometry. Sarcopenic obesity was defined using 29 definitions. Low handgrip strength was identified as < 27 kg in males and < 16 kg in females and poor physical performance was defined as gait speed ≤ 0.8 m/s. The prevalence of sarcopenic obesity ranged from 0.1 to 85.3% in males, and from 0 to 80.4% in females. Sarcopenic obesity was frequently associated with low handgrip strength (p < 0.05) in both males (14/17 definitions, 82.4%) and females (21/29 definitions, 72.4%). In very few definitions, sarcopenic obesity was associated with slow gait speed (males: 1/17 definitions [6.7%]; females: 2/29 [6.9%]). In conclusion, the prevalence of sarcopenic obesity varied greatly according to definitions and sarcopenic obesity was frequently associated with low handgrip strength.

show abstract

A review of telomere length in sarcopenia and frailty

et al. 2018

View full text Add to dashboard Cite

Sarcopenia and frailty are associated with several important health-related adverse events, including disability, loss of independence, institutionalization and mortality. Sarcopenia can be considered a biological substrate of frailty, and the prevalence of both these conditions progressively increases with age. Telomeres are nucleoprotein structures located at the end of linear chromosomes and implicated in cellular ageing, shorten with age, and are associated with various age-related diseases. In addition, telomere length (TL) is widely considered a molecular/cellular hallmark of the ageing process. This narrative review summarizes the knowledge about telomeres and analyzes for the first time a possible association of TL with sarcopenia and frailty. The overview provided by the present review suggests that leukocyte TL as single measurement, calculated by quantitative real-time polymerase chain reaction (qRT-PCR), cannot be considered a meaningful biological marker for complex, multidimensional age-related conditions, such as sarcopenia and frailty. Panels of biomarkers, including TL, may provide more accurate assessment and prediction of outcomes in these geriatric syndromes in elderly people.

show abstract

Sarcopenia, Telomere Length and Mortality: Nhanes 1999–2002

Cited by 6 publications

References 0 publications

Evaluation of sarcopenia, sarcopenic obesity, and phase angle in geriatric gastrointestinal cancer patients: before and after chemotherapy

Evaluation of sarcopenia, sarcopenic obesity, and phase angle in geriatric gastrointestinal cancer patients: before and after chemotherapy

Prevalence of Sarcopenic Obesity Using Different Definitions and the Relationship With Strength and Physical Performance in the Canadian Longitudinal Study of Aging

A review of telomere length in sarcopenia and frailty

Contact Info

Product

Resources

About